GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Champions Oncology CSBR · USD

Health Care · US listing · 🇺🇸 United States

Compare

4.84

+1.04%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Champions Oncology

From its filings with the US Securities and Exchange Commission

SEC filings

Champions Oncology is based in Baltimore, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CSBR. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 30 April 2026, it reported revenue of $59.4m and a net loss of $1.2m. At that date it held total assets of $27.0m and shareholders' equity of $3.9m.

In its own words

We are a technology-enabled research organization engaged in creating technology solutions to be utilized in drug discovery and development. Our research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. Our pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds.

At the core of our research platforms is our unique, proprietary bank of Patient Derived Xenograft (PDX) models. This preeminent bank of PDX models is deployed into advanced in vivo and ex vivo pharmacology platforms, providing an enhanced level of insight into therapeutic programs. We currently have approximately 1,500 PDX Models in our TumorBank that we believe reflect the characteristics of patients who enroll in clinical trials (late stage, pretreated and metastatic). This characteristic of our TumorBank is an important differentiator to other established PDX banks. We implant and expand these tumors in mice, which allows for future studies and additional characterization of the tumor. Additional analytical and pharmacology experimental platforms are also available to augment the information gained from studies performed.

Quoted from its 10-K, filed 27 Jul 2026. Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
30 Nov 1988
Employees
230
Head office
855 N. WOLFE STREET, BALTIMORE, MD, 21205
Incorporated in
DE
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. Ronnie MorrisChairman of the Board, since 2010$600,000
  • Mr. Robert BraininChief Executive Officer, Director, since 2021$83,156
  • Mr. David MillerChief Financial Officer$315,777
  • Mr. Joel AckermanIndependent Director, since 2010$118,418
  • Dr. Philip BreitfeldIndependent Director$86,319
  • Mr. Daniel MendelsonIndependent Director$90,939
  • Dr. David SidranskyIndependent Director, since 2007$85,028
  • Mr. Scott TobinIndependent Director$94,732

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
36
Environment
40
Social
32
Governance
36
Carbon reduction policy
No
Human rights policy
No

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.